FDA’s Abrams Spends 4 Minutes Discussing Social Media Guidance at ePharma Summit!
This just in: FDA Won't Issue Specific Guidance for Youtube, Facebook, or Twitter. Claims These Media Are Just Passing Fads! Now Back to Your Regularly-Scheduled TV Ad.
Orphan Drugs Now “Where the Money Is,” Says Willie Sutton’s Ghost
Why do pharma companies bother developing drugs for for a disorder affecting fewer than 200,000 people? Willie Sutton's ghost may have the answer.
FDA Drops Social Media from Its Guidance Agenda: Focuses Instead on Responsding to “Unsolicited”...
FDA's revised draft guidance calendar for year 2011 is missing 'Promotion of Prescription Drug Products Using Social Media Tools,
Pharma Marketing News Vol. 10, No. 9: 18 May 2011
Welcome to Volume 10, Issue #9 (18 MAY 2011) of Pharma Marketing News.
Digitally-Feeble Pharma
Is Your Brand a Digital Genius or a Feeble-Minded Idiot? When it comes to digital IQ, some brands are geniuses and some are feeble-minded idiots, according to the 'L2 Digital IQ Index' for pharmaceutical brands, a first-of-its kind measurement of the digital competence of 51 pharma brands across eight therapeutic categories.
Limiting Bias in Commercially Supported CME
Many critics of pharma-supported CME believe this support leads to bias. Between 9 May 2011 and 13 September 2011, readers of Pharma Marketing News were asked to answer a few short questions relating to potential bias in industry-supported CME programs and how to limit the need for industry funding of CME. The results are summarized in this article.
A Pharma Social Media Conspiracy Theory: Were Guidelines Held Hostage as Part if FDA’s...
Were FDA's infamous 14 warning letters to pharma a ploy to force Google into a $500M DOJ settlement regarding illegal online pharmacy ads? In addition, could FDA have been holding back issuing pharma social media guidelines -- which would include guidelines for displayig compliant information in space-limited applications such as Twitter AND Google Adwords -- until Google settled its case with the DOJ?
Without Free Gifts from Pharma to Docs, Would Research be Useless?
In a recent blog post, PhRMA said 'Without Promotion Research will be Useless.' To support its case, PhRMA cited 'an interesting opinion editorial' in the latest edition of the Annals of Emergency Medicine -- the medical journal of the American College of Emergency Physicians (ACEP). In the op-ed, entitled 'Limiting Gifts, Harming Patients,' Emory University economist Paul Rubin, Ph.D. expressed concern that ACEP policy regarding Gifts to Emergency Physicians from Industry 'could have the unfortunate effect of limiting the exchange of critical information between medicine makers and physicians about the benefits and risks of new medicines, how to use them properly and how best to diagnose the right candidates for particular treatments.'
The Pharmaguy Social Media Timeline&trade: A Record of Social Media Events Impacting the Pharmaceutical...
The long-awaited social media guidance from the FDA -- whenever it arrives -- may turn out to be nothing more than a stamp of approval on activities in which the industry is currently engaged. Practically every issue that FDA guidance is expected to address has already been handled independently by a few pioneering pharmaceutical companies. Rather than waiting for FDA's anti climatic guidelines, Pharmaguy decided to publish The Pharmaguy Social Media Timeline™ now, at a time when the industry already has set precedents in every social media application.
Pfizer, Show Us Your Social Media “Playbook”
Has It Been Found? What Does It Reveal About Pfizer's Social Media Implementation Plan?. Ray Kerins (@raykerins), Vice President of Worldwide Communications at Pfizer, talks about Pfizer's 'groundbreaking internal Social Media Playbook' but won't show it to us. What can be in the playbook? How many people does Pfizer dedicate to social media? This article discusses those questions and offers a peek into a playbook contender.
